Spry review

What it is

Spry is a weight-loss and anti-aging telehealth service selling five products: compounded semaglutide and compounded tirzepatide under Weight Loss, and BPC-157, NAD⁺ and sermorelin under Anti-Aging. It names three co-founders — Gabriel Mullins, Sara Yoder and Tyler Bowman — and states that its team has more than twenty years of experience, without publishing clinical credentials for any of them. It does not accept insurance but states it can supply documentation to help you submit a claim yourself. It holds LegitScript certification, displayed with a link to the public checker.

How it works

Asynchronous intake reviewed by a licensed nurse practitioner, stated in its own FAQ as happening within 24 hours, with no contracts and no commitment requirements. Naming three co-founders publicly is above the norm for this segment and worth crediting; not publishing any clinical credential for them is a straightforward miss, because the founders of a telehealth company are not the same thing as its prescribers, and the site does not name a medical director either. The bigger issue is the trust presentation. An "FDA Approved" badge in a trust-signals row is, on a site selling compounded semaglutide, tirzepatide and peptides, pointing at something that does not exist — none of those are FDA-approved finished drug products — and the counterbalancing disclosure that most competitors publish verbatim is absent from the homepage entirely. That is not a small formatting quibble on a page selling injectables. Also undisclosed: the states it serves, its pharmacy partner, whether that pharmacy is 503A or 503B, its corporate legal entity, its governing law and any refund terms beyond "no contracts". Its site is a client-side application whose static HTML is an empty shell, so we could not render its pages directly and the figures below come from our own record's verbatim capture.

Pricing transparency

Shown on the homepage, which is genuinely better than a sign-up wall, and unusable as a monthly comparison. The captured product tiles read "Starting at $249.00" for BPC-157, "Starting at $299.00" for NAD⁺ and "Starting at $249.00" for sermorelin, with compounded semaglutide at $199 and tirzepatide at $299. What none of them states is a billing period. "Starting at $249.00" could be a month, a quarter, a vial or a first payment, and the site does not resolve it — so we publish no monthly floor for Spry on either board rather than assume the most flattering reading. There is no membership fee stacked underneath, and no contract, both of which are stated plainly. Two things to establish before ordering: whether the figure recurs monthly and what happens to it when a provider raises your dose, since no dose ladder is published for any product. Ask both in writing.

Branded vs compounded

Compounded; not FDA-approved — a statement the site itself does not make, which is the core problem with this listing. Prescription required only if a licensed provider finds it appropriate. No pharmacy partner is named, no 503A or 503B designation is given, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, its three anti-aging products sit on three different tiers and are priced as though they were equivalent. Sermorelin is a GHRH analogue that stimulates your own pituitary — a real, well-characterised mechanism whose long-term human outcome data stays thin past short-term IGF-1 movement. Injected NAD⁺ has no controlled human outcome trials at all; the NAD⁺ forms with human trial data are the oral precursors NR and NMN, and what those trials show is a raised blood NAD⁺ level rather than a clinical outcome. BPC-157 is the weakest of the three: it has no controlled human outcome trials, its reputation rests on rodent work, and its presence on a menu is a reasonable signal of how a service selects what to sell. Individual results vary.

Pros and watch-outs

The evidence behind what Spry prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• BPC 157: what the evidence actually shows (and what it doesn't)

  The 'healing peptide' has a deep rodent literature and almost no human data. A straight read of where the science stands.

• NAD injections: how to get them near you or online, and what the evidence really says

  Subcutaneous NAD+ injections are sold as a cheaper, at-home alternative to the IV drip — via “near me” clinics or telehealth shipped to your door. They’re compounded, not FDA-approved, and have no outcome trials; oral NR/NMN precursors are the route with the human data.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

How Spry compares

A few alternatives worth a look, depending on what you’re optimizing for.

• STStackMD

  Buyers who want the vial concentration stated and will do the four-week-cycle maths themselves

  See StackMD →
• TMTaurus Meds

  Buyers who want the clinician network and pharmacies named and will confirm the recurring charge first

  See Taurus Meds →
• PLPlexusDx

  NAD⁺ at a published all-in monthly price with check-ins and no membership on top

  See PlexusDx →